Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Rong, Zhe ^a   Li, Li ^b   Fei, Fei ^b   Luo, Lailong ^b   Qu, Yang ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; CoCl2; Glibenclamide; Matrix metalloproteinase; Tientsin Albino 2

Indexed keywords

COBALT CHLORIDE; GELATINASE B; GLIBENCLAMIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OXYGEN SUPPLY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COBALT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYBURIDE; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM METASTASIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RNA, MESSENGER; TUMOR BURDEN;

EID: 84878259323     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-32     Document Type: Article

References (38)

1. Long-term risko f breast cancer recurrence: the need for extended adjuvant therapy. Kaufmann M, Rody A, J Cancer Res Clin Oncol 2005 131 487 494 10.1007/s00432-005-0668-x 15915367
2. Clusterin is associated with spontaneous breast cancer in TA2 mice. Sun B, Zhang S, Zhang D, Liu Y, Li Y, Rong Z, Zhu Y, Jia X, FEBS Lett 2007 581 17 3277 3282 10.1016/j.febslet.2007.06.021 17597618
3. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Robert V, Hideaki N, Circul Res 2003 92 8 827 839 10.1161/01.RES.0000070112. 80711.3D
4. An amino-bisphosphonate targets MMP9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. Giraudo E, Inoue M, Hanahan D, Clin Invest 2004 114 5 623 633
5. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. Park KS, Kim SJ, Kim KH, Kim JC, J Gastroenterol Hepatol 2011 26 2 391 397 10.1111/j.1440-1746.2010.06504.x 21261731
6. The role of hypoxia-inducible factor 1 in determining the properties of castrate-resistant prostate cancers. Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, Shulkes A, Baldwin GS, Patel O, PLoS One 2013 8 1 54251 10.1371/journal.pone.0054251 23342109
7. Hypoxia-a key regulatory factor in tumour growth. Harris AL, Nat Rev Cancer 2002 2 1 38 47 10.1038/nrc704 11902584
8. CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Piret JP, Mottet D, Raes M, Michiels C, Ann N Y Acad Sci 2002 973 443 447 10.1111/j.1749-6632.2002. tb04680.x 12485908
9. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J, Oncogene 2013 96 [Epub ahead of print] 10.1038/onc
10. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents? Marble A, Drugs 1971 1 2 109 115 10.2165/00003495-197101020-00001 4999930
11. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, Tsymbalyuk N, West GA, Gerzanich V, Nat Med 2006 12 4 433 440 10.1038/nm1390 16550187
12. Editorial: sulfonylureas differ in effects on ischemic preconditioning-is it time to retire glyburide? Riddle MC, J Clin Endocrinol Metabol 2003 88 2 528 530 10.1210/jc.2002-021971
13. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC Jr, Liu J, Cancer Lett 2012 326 2 176 182 10.1016/j.canlet.2012.08. 004 22902993
14. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB, Cancer Res 2002 62 4 1087 1092 11861387
15. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. Ahn HJ, Kim YS, Kim JU, Han SM, Shin JW, Yang HO, J Cell Biochem 2004 91 5 1043 1052 10.1002/jcb.20006 15034938
16. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Marshall SF, Clarke CA, Deapen D, Henderson K, Largent J, Neuhausen SL, Reynolds P, Ursin G, Horn-Ross PL, Stram DO, Templeman C, Bernstein L, Breast Cancer Res 2010 12 1 4 10.1186/bcr2467 20064209
17. Time trends, estimates and projects for breast cancer incidence and mortality in China. Yang L, Li LD, Chen YD, Parkin DM, Zhonghua Zhong Liu Za Zhi 2006 28 6 438 440 17152490
18. Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Shin HR, Joubert C, Boniol M, Hery C, Ahn SH, Won YJ, Nishino Y, Sobue T, Chen CJ, You SL, Mirasol-Lumague MR, Law SC, Mang O, Xiang YB, Chia KS, Rattanamongkolgul S, Chen JG, Curado MP, Autier P, Cancer Causes Control 2010 21 11 1777 1785 10.1007/s10552-010-9604-8 20559704
19. Age-period-cohort projections of breast cancer incidence in a rapidly transitioning Chinese population. Wong IO, Cowling BJ, Schooling CM, Leung GM, Int J Cancer 2007 121 7 1556 1563 10.1002/ijc.22731 17437268
20. Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC, J Natl Cancer Inst 2013 105 2 104 112 10.1093/jnci/djs506 23264681
21. Combined treatment with exogenous estradiol and progesterone increases the incidence of breast cancer in TA2 mice without ovaries. Yin Y, Yang Z, Zhang S, Cancer Lett 2011 311 2 171 176 10.1016/j.canlet.2011.07.011 21852035
22. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y, Clin Cancer Res 2008 14 21 7050 7059 10.1158/1078-0432. CCR-08-0520 18981002
23. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X, Cancer Lett 2007 249 2 188 197 10.1016/j.canlet.2006.08.016 16997457
24. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Zhang S, Li M, Zhang D, Xu S, Wang X, Liu Z, Zhao X, Sun B, Lab Invest 2009 89 5 575 586 10.1038/labinvest.2009.20 19290005
25. Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. Pilati P, Mocellin S, Miotto D, Fitta C, Casara D, Ori C, Scalerta R, Nitti D, Lise M, Rossi CR, Oncol Rep 2004 12 895 901 15375519
26. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Guadagni S, Santinami M, Patuzzo R, Pilati PL, Miotto D, Deraco M, Rossi CR, Fiorentini G, Di Filippo F, Valenti M, Amicucci G, Melanoma Res 2003 13 51 58 10.1097/00008390-200302000-00009 12569285
27. Effects of transition metals on the expression of the erythropoietin gene: further evidence that the oxygen sensor is a heme protein. Ho VT, Bunn HF, Biochem Biophys Res Commun 1996 223 1 175 180 10.1006/bbrc.1996.0865 8660366
28. Sulphonylureas in NIDDM. Groop LC, Diabetes Care 1992 15 6 737 754 10.2337/diacare.15.6.737 1600834
29. Voltage-gated potassium channels in cell proliferation. Pardo LA, Physiology 2004 19 285 292 10.1152/physiol.00011.2004 15381757
30. Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane release in HepG2 human hepatoblastoma cells. Kim JA, Kang YS, Lee SH, Lee EH, Yoo BH, Lee YS, Biochem Biophys Res Commun 1999 261 682 688 10.1006/bbrc.1999.1108 10441486
31. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Qian X, Li J, Ding J, Wang Z, Duan L, Hu G, Biochem Pharmacol 2008 76 1705 1715 10.1016/j.bcp.2008.09.009 18840412
32. Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. Núñez M, Medina V, Cricco G, Croci M, Cocca C, Rivera E, Bergoc R, Martín G, BMC Pharmacol Toxicol 2013 14 6 10.1186/2050-6511-14-6 23311706
33. Association of Epstein-Barr virus with tumor cell proliferation: clinical implication in nasopharyngeal carcinoma. Kijima T, Kinukawa N, Gooding WE, Uno M, Int J Oncol 2001 18 3 479 485 11179475
34. Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, Cohen H, Sabo E, Histopathology 2002 41 6 519 525 10.1046/j.1365-2559.2002.01444.x 12460204
35. Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Saadoun D, Bieche I, Authier FJ, Laurendeau I, Jambou F, Piette JC, Vidaud M, Maisonobe T, Cacoub P, Arthritis Rheum 2007 56 4 1315 1324 10.1002/art.22456 17393409
36. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M, Cancer Causes Control 2000 89 4 715 723
37. Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Dean RA, Overall CM, Mol Cell Proteomics 2007 6 4 611 623 10.1074/mcp.M600341-MCP200 17200105
38. Cancer as a metabolic disease. Seyfried TN, Shelton LM, Nutr Metab (Lond) 2010 7 7 10.1186/1743-7075-7-7